Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis
NCT ID: NCT02428803
Last Updated: 2021-10-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
21 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-04-30
Study Completion Date
2020-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Home dialysis patients must be seen in a face to face visit on a monthly basis. For patients who live remotely these visits may impact their quality of life due to the amount of time needed to attend these visits. The central hypothesis is that implementation of telemedicine visits as a substitute for the 2 out of 3 monthly face-to-face visits over a 6 month period will improve quality of life as judged by the quality of life (QoL) indices Kidney Disease Quality of Life - Short Form and the Illness Intrusiveness Ratings Scale when compared to QoL scales taken during a time period when the patient is on standard of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis: A Multicentre Randomized Controlled Trial
NCT02670512
End-Stage Renal Disease
COMPLETED
NA
Evaluation of the Integrated Home Dialysis Model
NCT02278159
Kidney Failure, Chronic
COMPLETED
Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients
NCT02128347
Hemodialysis, Home
Peritoneal Dialysis
COMPLETED
NA
Telemonitoring Impact by the ApTelecare Software in Dialysis Patient
NCT03927300
Chronic Renal Failure
Dialysis Related Complication
COMPLETED
Improving Adherence in Renal Dialysis Patients Through Electronic Interventions
NCT02970201
Endstage Renal Disease
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Peritoneal Dialysis is used by over 100,000 patients worldwide but only about 7% of patients in the United States. 1 As it is much less expensive than its in-center hemodialysis counterpart and provides improved quality of life, strategies are needed to increase its utilization. One potential barrier to peritoneal dialysis is the geographic barriers to care which exist in geographically diverse and large countries such as Canada, India, Australia, and the United States. 2,3 Access to an experienced home dialysis unit is limited in many parts of the United States and can contribute to low utilization rates by physician discomfort with the therapy as well as increased technique failure rates with inexperienced centers. 4-7 Prakash et al recently have shown that only 55% of dialysis units are certified to provide home dialysis. 8 In more rural networks such as network 8 (Alabama, Mississippi, and Tennessee), this number drops to 38% thus increasing the geographic barriers to the provision of home dialysis care. Patients currently living in rural areas and on a home therapy are faced with long commutes and time commitments adding up to significant financial hardships for the patients. Furthermore, these commutes impact quality of life. Telemedicine and telemonitoring may provide a means to bridge these geographic barrier thus improving access to home dialysis care and improving patient quality of life on the therapy and thus increasing its utilization.
The use of telemedicine in the provision of home dialysis care has received very limited attention worldwide and even less in the United States. Early studies using telemedicine in remote care suffered from high costs of implementing secure T1 lines and limited technology.9 Gallar et al in Spain published 2 years of experience using alternating videoconferencing visits and standard hospitalized visits, showing cost savings, ability to evaluate the patient for edema and exit site evaluation, as well as decreased time associated with each visit. 10 Nakamoto et al. in Japan published on their tool to transmit blood pressures, glucose readings remotely etc. 11 Since these initial studies and conceptualization of telemedicine, technology has increased at a very fast pace. Videoconferencing technology has become much smaller, more sophisticated, easier to use, and more inexpensive making it a mainstay in daily life including applications such as face time and skype. Technology literacy as well has continued to increase since early 2000. A recent survey among peritoneal dialysis patients showed that 88% owned a computer and 94% knew how to use a computer. 12 Furthermore, 83% of patients wished to participate in telemedicine. 12 It is within this environment that telemedicine and the application to home dialysis may begin to transform the delivery of care in home dialysis thus increasing peritoneal dialysis utilization by improving convenience of the therapy and improving the quality of life. Such interventions are already gaining popularity in countries such as India. 3 Studies are needed to determine the feasibility of telemedicine in the provision of home dialysis care in the United States and if quality of life of patients using this mechanism are improved. Furthermore, studies showing outcomes are similar if not improved using telemedicine are needed.
The long-term goal of this project is to improve access to peritoneal dialysis care and the quality of lives of patients on dialysis by evaluating ways to eliminate the geographic barrier. The objective here is to determine if specifically telemedicine has this capacity. By evaluating and establishing a framework by which home dialysis care could be provided via telemedicine and determining the impact on quality of life for these patients, policy could be informed as to coverage of telemedicine as a substitute for the current face-to-face requirement by Medicare. Furthermore, this intervention has the possibility of improving quality of life and if effective possibly increasing the utilization of peritoneal dialysis both by patients rural and urban due to increased convenience of the therapy with respect to in-center hemodialysis. The central hypothesis is that implementation of telemedicine visits as a substitute for the 2 out of 3 monthly face-to-face visits over a 6 month period will improve quality of life as judged by the quality of life (QoL) indices Kidney Disease Quality of Life - Short Form and the Illness Intrusiveness Ratings Scale when compared to QoL scales taken during a time period when the patient is on standard of care.
Specific Aims
1. Determine the impact of telemedicine on quality of life as indicated two quality of life surveys: 1) The KDQOL- SF and the Illness Intrusiveness Ratings Scale .
The investigators postulate that patients, during the telemedicine intervention will improve the quality of life scores on the KDQOL-SF form by the minimum clinically significant change of 3 points, as compared to themselves during a time period of standard of care visits (Not telemedicine).
2. Determine the feasibility of the use of telemedicine and remote monitoring in the provision of care for peritoneal dialysis patients as a substitute for two out of 3 monthly face-to-face visits over a 6 month period.
Based on the work by Nayak et al. in India, the investigators feel that telemedicine visits as a substitute for the face-to-face visit will be both feasible and advantageous.
3. Obtain preliminary data on efficacy of the intervention with regards to outcomes with a composite endpoint of episodes of peritonitis and hospitalizations.
The investigators postulate that there will be either no difference in outcomes or an improvement in outcomes in the telemedicine intervention arm.
Study Design:
Patients will be recruited from the University of Alabama at Birmingham Peritoneal Dialysis Unit. All patient's addresses are known and will be screened in order to determine inclusion criteria. Upon enrollment, patients will be administered the KDQOL-SF and the IIRS. Patient will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. Data will be collected during this time regarding hospitalizations, peritonitis, technique failures, and access procedures. Monthly labwork including hemoglobin, phosphorus, parathyroid level, iron, total iron binding capacity, and ferritin will also be collected. At the end of 6 months the KDQOL-SF and IIRS will again be administered.
The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely.
In order to do this, the investigators have partnered with the Alabama Department of Public Health. During the telemedicine visits, the patient will present to their county health department which are now outfitted with the capability to provide interactive telemedicine visits.
Exam: The patient will be examined during this telemedicine encounter using blue-tooth stethoscopes, placed on the patients chest by personnel in the county health department. The exit site will be examined using the remote camera. Fluid status will be monitored by both lung exam, weights which the patient does on a routine basis, and the examination of pitting edema as done over a telemedicine interface.
Labs- On the quarterly "standard" visit during the telemedicine intervention, the patient will be given 2 preaddressed and prestamped containers with all vials needed to collect their monthly labs. The patient during their telemedicine visits will bring this container with blood collection tubes to the county health department. There, personnel a the health department will perform phlebotomy, using the predetermined blood collection tubes. Once filled, these tubes will be sent in the prestamped container to the Davita Central Lab for further processing. In this way, no additional cost for labs will be incurred, and lab results will be standardized in one central lab.
Flow sheets: Patients records of therapy will be obtained using the Baxter ProCard. The patient will be trained on these cards prior to going to the telemedicine arm of the study. The patients will then be given 2 cards. Patients will use 1 procard for the month, and prior to their telemedicine visit will send this card in for download. Patients will then begin to use thesecond card, the previous card will be sent back to the patient via mail prior to their second visit such that it is had for their 3rd month.
Remote QoL Surveys: Patients will be administered either over the phone or on a paper form depending on literacy the KDQOL-SF and the IIRS survey on Visit 3, and Visit 6.
After completion of telemedicine arm, patients will return to Standard of Care and after 2 months of being back on standard of care, KDQOL-SF and IIRS again will be administered.
Peritoneal Dialysis is used by over 100,000 patients worldwide but only about 7% of patients in the United States. 1 As it is much less expensive than its in-center hemodialysis counterpart and provides improved quality of life, strategies are needed to increase its utilization. One potential barrier to peritoneal dialysis is the geographic barriers to care which exist in geographically diverse and large countries such as Canada, India, Australia, and the United States. 2,3 Access to an experienced home dialysis unit is limited in many parts of the United States and can contribute to low utilization rates by physician discomfort with the therapy as well as increased technique failure rates with inexperienced centers. 4-7 Prakash et al recently have shown that only 55% of dialysis units are certified to provide home dialysis. 8 In more rural networks such as network 8 (Alabama, Mississippi, and Tennessee), this number drops to 38% thus increasing the geographic barriers to the provision of home dialysis care. Patients currently living in rural areas and on a home therapy are faced with long commutes and time commitments adding up to significant financial hardships for the patients. Furthermore, these commutes impact quality of life. Telemedicine and telemonitoring may provide a means to bridge these geographic barrier thus improving access to home dialysis care and improving patient quality of life on the therapy and thus increasing its utilization.
The use of telemedicine in the provision of home dialysis care has received very limited attention worldwide and even less in the United States. Early studies using telemedicine in remote care suffered from high costs of implementing secure T1 lines and limited technology.9 Gallar et al in Spain published 2 years of experience using alternating videoconferencing visits and standard hospitalized visits, showing cost savings, ability to evaluate the patient for edema and exit site evaluation, as well as decreased time associated with each visit. 10 Nakamoto et al. in Japan published on their tool to transmit blood pressures, glucose readings remotely etc. 11 Since these initial studies and conceptualization of telemedicine, technology has increased at a very fast pace. Videoconferencing technology has become much smaller, more sophisticated, easier to use, and more inexpensive making it a mainstay in daily life including applications such as face time and skype. Technology literacy as well has continued to increase since early 2000. A recent survey among peritoneal dialysis patients showed that 88% owned a computer and 94% knew how to use a computer. 12 Furthermore, 83% of patients wished to participate in telemedicine. 12 It is within this environment that telemedicine and the application to home dialysis may begin to transform the delivery of care in home dialysis thus increasing peritoneal dialysis utilization by improving convenience of the therapy and improving the quality of life. Such interventions are already gaining popularity in countries such as India. 3 Studies are needed to determine the feasibility of telemedicine in the provision of home dialysis care in the United States and if quality of life of patients using this mechanism are improved. Furthermore, studies showing outcomes are similar if not improved using telemedicine are needed.
The long-term goal of this project is to improve access to peritoneal dialysis care and the quality of lives of patients on dialysis by evaluating ways to eliminate the geographic barrier. The objective here is to determine if specifically telemedicine has this capacity. By evaluating and establishing a framework by which home dialysis care could be provided via telemedicine and determining the impact on quality of life for these patients, policy could be informed as to coverage of telemedicine as a substitute for the current face-to-face requirement by Medicare. Furthermore, this intervention has the possibility of improving quality of life and if effective possibly increasing the utilization of peritoneal dialysis both by patients rural and urban due to increased convenience of the therapy with respect to in-center hemodialysis. The central hypothesis is that implementation of telemedicine visits as a substitute for the 2 out of 3 monthly face-to-face visits over a 6 month period will improve quality of life as judged by the quality of life (QoL) indices Kidney Disease Quality of Life - Short Form and the Illness Intrusiveness Ratings Scale when compared to QoL scales taken during a time period when the patient is on standard of care.
Specific Aims
1. Determine the impact of telemedicine on quality of life as indicated two quality of life surveys: 1) The KDQOL- SF and the Illness Intrusiveness Ratings Scale .
The investigators postulate that patients, during the telemedicine intervention will improve the quality of life scores on the KDQOL-SF form by the minimum clinically significant change of 3 points, as compared to themselves during a time period of standard of care visits (Not telemedicine).
2. Determine the feasibility of the use of telemedicine and remote monitoring in the provision of care for peritoneal dialysis patients as a substitute for two out of 3 monthly face-to-face visits over a 6 month period.
Based on the work by Nayak et al. in India, the investigators feel that telemedicine visits as a substitute for the face-to-face visit will be both feasible and advantageous.
3. Obtain preliminary data on efficacy of the intervention with regards to outcomes with a composite endpoint of episodes of peritonitis and hospitalizations.
The investigators postulate that there will be either no difference in outcomes or an improvement in outcomes in the telemedicine intervention arm.
Study Design:
Patients will be recruited from the University of Alabama at Birmingham Peritoneal Dialysis Unit. All patient's addresses are known and will be screened in order to determine inclusion criteria. Upon enrollment, patients will be administered the KDQOL-SF and the IIRS. Patient will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. Data will be collected during this time regarding hospitalizations, peritonitis, technique failures, and access procedures. Monthly labwork including hemoglobin, phosphorus, parathyroid level, iron, total iron binding capacity, and ferritin will also be collected. At the end of 6 months the KDQOL-SF and IIRS will again be administered.
The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely.
In order to do this, the investigators have partnered with the Alabama Department of Public Health. During the telemedicine visits, the patient will present to their county health department which are now outfitted with the capability to provide interactive telemedicine visits.
Exam: The patient will be examined during this telemedicine encounter using blue-tooth stethoscopes, placed on the patients chest by personnel in the county health department. The exit site will be examined using the remote camera. Fluid status will be monitored by both lung exam, weights which the patient does on a routine basis, and the examination of pitting edema as done over a telemedicine interface.
Labs- On the quarterly "standard" visit during the telemedicine intervention, the patient will be given 2 preaddressed and prestamped containers with all vials needed to collect their monthly labs. The patient during their telemedicine visits will bring this container with blood collection tubes to the county health department. There, personnel a the health department will perform phlebotomy, using the predetermined blood collection tubes. Once filled, these tubes will be sent in the prestamped container to the Davita Central Lab for further processing. In this way, no additional cost for labs will be incurred, and lab results will be standardized in one central lab.
Flow sheets: Patients records of therapy will be obtained using the Baxter ProCard. The patient will be trained on these cards prior to going to the telemedicine arm of the study. The patients will then be given 2 cards. Patients will use 1 procard for the month, and prior to their telemedicine visit will send this card in for download. Patients will then begin to use thesecond card, the previous card will be sent back to the patient via mail prior to their second visit such that it is had for their 3rd month.
Remote QoL Surveys: Patients will be administered either over the phone or on a paper form depending on literacy the KDQOL-SF and the IIRS survey on Visit 3, and Visit 6.
After completion of telemedicine arm, patients will return to Standard of Care and after 2 months of being back on standard of care, KDQOL-SF and IIRS again will be administered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
ESRD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CROSSOVER
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine
Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 19 or greater
* On Peritoneal Dialysis
* Living in a different county than that of the UAB Home Dialysis Unit ( Any county other than Jefferson County)
* Patients have to be stable on therapy for 2 months prior to enrollment
* On Peritoneal Dialysis
* Living in a different county than that of the UAB Home Dialysis Unit ( Any county other than Jefferson County)
* Patients have to be stable on therapy for 2 months prior to enrollment
Exclusion Criteria
* Living in Jefferson County
Minimum Eligible Age
19 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baxter Healthcare Corporation
INDUSTRY
Sponsor Role
collaborator
University of Alabama at Birmingham
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric Wallace
Assistant Professor Medicine - Nephrology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Wallace, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB
Birmingham, Alabama, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
US Renal Data System: Bethesda, US Department of Public Health and Human Services, Public Health Service, National Institutes of Health, 2013
Reference Type
BACKGROUND
Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, Manns B; Alberta Kidney Disease Network. Mortality of Canadians treated by peritoneal dialysis in remote locations. Kidney Int. 2007 Oct;72(8):1023-8. doi: 10.1038/sj.ki.5002443. Epub 2007 Jul 18.
Reference Type
BACKGROUND
Nayak A, Karopadi A, Antony S, Sreepada S, Nayak KS. Use of a peritoneal dialysis remote monitoring system in India. Perit Dial Int. 2012 Mar-Apr;32(2):200-4. doi: 10.3747/pdi.2011.00124. No abstract available.
Reference Type
BACKGROUND
Afolalu B, Troidle L, Osayimwen O, Bhargava J, Kitsen J, Finkelstein FO. Technique failure and center size in a large cohort of peritoneal dialysis patients in a defined geographic area. Perit Dial Int. 2009 May-Jun;29(3):292-6.
Reference Type
BACKGROUND
Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant. 2002 Sep;17(9):1655-60. doi: 10.1093/ndt/17.9.1655.
Reference Type
BACKGROUND
Guo A, Mujais S. Patient and technique survival on peritoneal dialysis in the United States: evaluation in large incident cohorts. Kidney Int Suppl. 2003 Dec;(88):S3-12. doi: 10.1046/j.1523-1755.2003.08801.x.
Reference Type
BACKGROUND
Prakash S, Coffin R, Schold J, Lewis SA, Gunzler D, Stark S, Howard M, Rodgers D, Einstadter D, Sehgal AR. Travel distance and home dialysis rates in the United States. Perit Dial Int. 2014 Jan-Feb;34(1):24-32. doi: 10.3747/pdi.2012.00234.
Reference Type
BACKGROUND
Gallar P, Vigil A, Rodriguez I, Ortega O, Gutierrez M, Hurtado J, Oliet A, Ortiz M, Mon C, Herrero JC, Lentisco C. Two-year experience with telemedicine in the follow-up of patients in home peritoneal dialysis. J Telemed Telecare. 2007;13(6):288-92. doi: 10.1258/135763307781644906.
Reference Type
BACKGROUND
Nakamoto H, Hatta M, Tanaka A, Moriwaki K, Oohama K, Kagawa K, Wada K, Suzuki H. Telemedicine system for home automated peritoneal dialysis. Adv Perit Dial. 2000;16:191-4.
Reference Type
BACKGROUND
Lew SQ, Sikka N. Are patients prepared to use telemedicine in home peritoneal dialysis programs? Perit Dial Int. 2013 Nov-Dec;33(6):714-5. doi: 10.3747/pdi.2012.00203. No abstract available.
Reference Type
BACKGROUND
Fong E, Bargman JM, Chan CT. Cross-sectional comparison of quality of life and illness intrusiveness in patients who are treated with nocturnal home hemodialysis versus peritoneal dialysis. Clin J Am Soc Nephrol. 2007 Nov;2(6):1195-200. doi: 10.2215/CJN.02260507. Epub 2007 Oct 10.
Reference Type
BACKGROUND
Diamant MJ, Young A, Gallo K, Xi W, Suri RS, Garg AX, Moist LM. Hemodialysis in a satellite unit: clinical performance target attainment and health-related quality of life. Clin J Am Soc Nephrol. 2011 Jul;6(7):1692-9. doi: 10.2215/CJN.07650810. Epub 2011 May 12.
Reference Type
BACKGROUND
Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999 Feb;15(2):141-55. doi: 10.2165/00019053-199915020-00003.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X141112004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis
NCT02044614
TERMINATED
NA
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
NCT03019159
WITHDRAWN
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
NCT04034966
UNKNOWN
NA
Virtual Ward for Home Dialysis
NCT01912001
COMPLETED
NA
Evaluation of a Virtual Home Dialysis Mentoring Program (Home)
NCT04806126
COMPLETED
Assisted Peritoneal Dialysis: A Feasibility Study
NCT04319185
UNKNOWN
NA
Integrated Patient Care Intradialysis Programme in Hemodialysis Through a Virtual Health Platform
NCT04823286
RECRUITING
NA
Use of a Bimodal Solution for Peritoneal Dialysis
NCT01242904
COMPLETED
PHASE2
Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis
NCT02133313
COMPLETED
A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis
NCT00214721
COMPLETED
PHASE3
Hemodialysis in the Elderly (70yrs & Older)
NCT03065972
UNKNOWN
NA
Urgent-start Peritoneal Dialysis in ESRD Patients：A Multi-center Study
NCT02946528
COMPLETED
NA
Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
NCT02695641
WITHDRAWN
EARLY_PHASE1
Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure
NCT00280072
TERMINATED
PHASE2
A Video Decision Support Tool to Assist Elderly Patients in ESRD Treatment Decision-making
NCT02698722
COMPLETED
NA
Online Hemodiafiltration vs Conventional Hemodialysis in Acute Kidney Injury
NCT04525092
COMPLETED
NA
Human Factors Validation Testing for the Peripal System; a Manual Connection Assist Device for Peritoneal Dialysis Devices
NCT04292210
COMPLETED
NA
Virtual Reality in End Stage Kidney Disease
NCT06356168
NOT_YET_RECRUITING
NA
Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury
NCT02630355
TERMINATED
PHASE2
Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.
NCT06257134
NOT_YET_RECRUITING
NA
Light Therapy in End Stage Kidney Disease
NCT06310161
NOT_YET_RECRUITING
NA
Feasibility Study of a mHealth Platform for Remote Patient Monitoring of CKD and Peritoneal Dialysis Patients
NCT05012020
COMPLETED
NA
Improving Outcomes in Peritoneal Dialysis
NCT02207751
WITHDRAWN
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
NCT03874117
COMPLETED
NA
Acupoint Stimulation Improves Fatigue and Sleep Quality in Patients With Postdialysis
NCT06028685
COMPLETED
NA